von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins
- 21 November 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (6), 2424-2429
- https://doi.org/10.1182/blood-2006-06-028241
Abstract
Von Willebrand factor (VWF) protects factor VIII (FVIII) from proteolysis and mediates the initial contact of platelets with the injured vessel wall, thus playing an important role in hemostasis and thrombosis. VWF is crucial for the formation of occlusive thrombi at arterial shear rates. However, with only a few conflicting studies published, the role of VWF in venous thrombosis is still unclear. Using gene-targeted mice, we show that in ferric chloride–injured veins platelet adhesion to subendothelium is decreased and thrombus growth is impaired in VWF−/− mice when compared with wild type (WT). We also observed increased embolization in the VWF−/− mice, which was due to lower FVIII levels in these mice as recombinant factor VIII (r-FVIII) restored thrombus stability. Despite normalization of blood clotting time and thrombus stability after r-FVIII infusion, the VWF−/− venules did not occlude. Transgenic platelets lacking the VWF receptor GPIbα extracellular domain showed decreased adhesion to injured veins. But, after a delay, all the injured venules occluded in these transgenic mice. Thus, VWF likely uses other adhesion receptors besides GPIbα in thrombus growth under venous shear conditions. Our studies document crucial roles for VWF and FVIII in experimental thrombosis under venous flow conditions in vivo.Keywords
This publication has 36 references indexed in Scilit:
- The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosisProceedings of the National Academy of Sciences of the United States of America, 2006
- Characterization of Recessive Severe Type 1 and 3 von Willebrand Disease (VWD), Asymptomatic Heterozygous Carriers Versus Bloodgroup O-Related von Willebrand Factor Deficiency, and Dominant Type 1 VWDClinical and Applied Thrombosis/hemostasis, 2006
- Decreased Plasma Fibronectin Leads to Delayed Thrombus Growth in Injured ArteriolesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Systemic antithrombotic effects of ADAMTS13The Journal of Experimental Medicine, 2006
- Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndromeBlood, 2002
- Contact--How Platelets Touch von Willebrand FactorScience, 2002
- A revised model of platelet aggregationJCI Insight, 2000
- Targeted disruption of the mouse factor VIII gene produces a model of haemophilia ANature Genetics, 1995
- Cell Biology Of Von Willebrand FactorAnnual Review of Cell and Developmental Biology, 1990
- Stabilization of Factor VIII in Plasma by the von Willebrand FactorJCI Insight, 1977